

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right  
truncation  
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new  
classification scheme  
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 13 OCT 19 E-mail format enhanced  
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:33:00 ON 06 NOV 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY      SESSION  
1.05      1.05

FILE 'REGISTRY' ENTERED AT 14:36:04 ON 06 NOV 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 NOV 2006    HIGHEST RN 912451-62-8  
DICTIONARY FILE UPDATES:    5 NOV 2006    HIGHEST RN 912451-62-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10507006.str



chain nodes :

9 15 16 17 20 21 22 23 24 25 27 28 29 30 31 32

ring nodes :

1 2 3 4 5 6 7 8 11 12 13 14

chain bonds :

1-27 1-28 2-29 2-30 5-31 5-32 6-9 11-20 12-16 13-15 16-17 17-25 20-21  
21-22 21-24 22-23

ring bonds :  
 1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8 7-11 8-14 11-12 12-13 13-14  
 exact/norm bonds :  
 1-2 1-5 1-27 1-28 2-3 2-29 2-30 3-4 3-6 4-5 4-8 5-31 5-32 6-7 6-9  
 11-20 12-16 13-15 16-17 17-25 20-21 21-22 21-24 22-23  
 normalized bonds :  
 7-8 7-11 8-14 11-12 12-13 13-14  
 isolated ring systems :  
 containing 1 :

G1:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:Atom  
 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 20:Atom 21:CLASS  
 22:CLASS 23:Atom 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS  
 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:36:34 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE,

100.0% PROCESSED 5 ITERATIONS  
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:36:38 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS 12 ANSWERS  
SEARCH TIME: 00.00.01

L3 12 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.99

FILE 'CAPLUS' ENTERED AT 14:36:43 ON 06 NOV 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Nov 2006 VOL 145 ISS 20  
FILE LAST UPDATED: 5 Nov 2006 (20061105/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:436085 CAPLUS

DOCUMENT NUMBER: 143:133316


TITLE: Hantzsch Synthesis of Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridines: Partial Agonists of the Calcitonin Receptor

AUTHOR(S): Boros, Eric E.; Cowan, David J.; Cox, Richard F.; Mebrahtu, Makda M.; Rabinowitz, Michael H.; Thompson, James B.; Wolfe, Lawrence A., III

CORPORATE SOURCE: GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA

SOURCE: Journal of Organic Chemistry (2005), 70(13), 5331-5334


PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 143:133316  
 GI



I

- AB Small mol. calcitonin receptor agonists are of potential utility in the treatment and prevention of osteoporosis. 3-Amino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one (I) was a useful intermediate in the synthesis of pyrazolopyridine calcitonin receptor partial agonists II [R = 2-furylmethyl, 3-pyridylmethyl, 3-FC6H4CH2, 1-indanyl; X = O, S, CH:CH; Y = F, CF3]. The corresponding dihydropyridines were conveniently prepared by reaction of I with Knoevenagel adducts of 4-YC6H4CH2CH2COCH2CO2Et (III) or by a three component reaction with I, III, and 4-OCHC6H4CO2H. Oxidation to pyridine and amide formation afforded I.
- IT 858671-20-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (Hantzsch synthesis of pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridines as partial agonists of the calcitonin receptor)
- RN 858671-20-2 CAPLUS
- CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-furanyl]-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:737759 CAPLUS

DOCUMENT NUMBER: 139:261291

TITLE: Preparation of condensed heterocyclic compounds such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivatives as calcitonin agonists

INVENTOR(S): Bhandari, Ashok; Boros, Eric Eugene; Cowan, David John; Handlon, Anthony Louis; Hyman, Clifton Earl; Oplinger, Jeffrey Alan; Rabinowitz, Michael Howard; Turnbull, Philip Stewart

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 174 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076440	A1	20030918	WO 2003-US5605	20030224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003213266	A1	20030922	AU 2003-213266	20030224
US 2005107419	A1	20050519	US 2003-507006	20030224
PRIORITY APPLN. INFO.:			US 2002-362011P	P 20020306
			WO 2003-US5605	W 20030224

OTHER SOURCE(S): MARPAT 139:261291

GI



AB The title compds. [I; R = each (un)substituted aryl, heteroaryl, alkyl, or cycloalkyl, further wherein said aryl, heteroaryl, alkyl, or cycloalkyl; Z = H, alkyl, halogen, CO<sub>2</sub>R<sub>5</sub>, CON(R<sub>5</sub>)<sub>2</sub>, CONHN(R<sub>5</sub>)<sub>2</sub>, NHCON(R<sub>5</sub>)<sub>2</sub>, SO<sub>2</sub>N(R<sub>5</sub>)<sub>2</sub>, CH<sub>2</sub>NHCOR<sub>5</sub>, NO<sub>2</sub>, N(R<sub>5</sub>)<sub>2</sub>, NHCOR<sub>5</sub>, N(R<sub>5</sub>)SO<sub>2</sub>N(R<sub>5</sub>)<sub>2</sub>, OR<sub>5</sub>, CH<sub>2</sub>N(R<sub>5</sub>)<sub>2</sub>, CH<sub>2</sub>CON(R<sub>5</sub>)<sub>2</sub>, CH<sub>2</sub>CO<sub>2</sub>R<sub>5</sub>, (un)substituted heteroaryl; R<sub>5</sub> = independently H, alkyl, trifluoromethyl, each (un)substituted aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocyclyl, fused cycloalkylaryl, or fused heterocyclylaryl; R<sub>1</sub> = H, alkyl, CO<sub>2</sub>R<sub>5</sub>, COR<sub>5</sub>, CON(R<sub>5</sub>)<sub>2</sub>, cyano, NO<sub>2</sub>, N(R<sub>5</sub>)<sub>2</sub>, SO<sub>2</sub>R<sub>5</sub>, SO<sub>2</sub>N(R<sub>5</sub>)<sub>2</sub>, NHCOR<sub>5</sub>, NHCON(R<sub>5</sub>)<sub>2</sub>; R<sub>2</sub> = alkyl, CF<sub>3</sub>, alkoxy, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyaryl, further wherein said alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be substituted with one or more of halogen, CF<sub>3</sub>, or alkoxy; or R<sub>1</sub> and R<sub>2</sub> combine to form a 5- or 6-membered ring, optionally containing one or more heteroatom, optionally containing one or more degrees of unsatn., and optionally substituted one or more times with oxo, hydroxy, halogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, further wherein said alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be substituted with one or more of halogen, CF<sub>3</sub>, or alkoxy; A = C, N; Y = C, N; X = S, O, N(R<sub>5</sub>), C(R<sub>5</sub>)<sub>2</sub>, SO<sub>2</sub>; n = 1, 2, 3, or 4], salts, solvates, and pharmaceutically functional derivs. thereof are prepared These compds. are useful in the treatment and prevention of diseases or conditions which are related to irregular calcification or those mediated by calcitonin. They are used in therapies for osteopenia and osteoporosis in men and women; reduction in the risk of fractures, both vertebral and nonvertebral; Paget's disease; bone fracture or deficiency; primary or secondary hyperparathyroidism; periodontal disease or defect; metastatic bone disorder; osteolytic bone disease; post-plastic surgery; post-prosthetic joint surgery; postdental implantation; hypercalcemia; bone pain, general pain, and hyperalgesia; conditions associated with inhibiting gastric secretion; gastrointestinal disorders; osteoarthritis and rheumatoid arthritis; renal osteodystrophy; obesity by induction of satiety; and male infertility. Thus, 4-[3-(Ethoxycarbonyl)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl]benzoic acid was condensed with furfurylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and HOBt-H<sub>2</sub>O in DMF at room temperature for 4 h to give 2-[2-(4-fluorophenyl)ethyl]-4-[4-[(2-furylmethyl)amino]carbonyl]phenyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylate (II). In an CRE-luciferase reporter assay, II activated the human calcitonin-2 receptor (HCT2R) expressed in CHO-6CRE-luciferase cells with E<sub>50</sub> of ≤10 nM.

IT 603998-46-5P 603998-48-7P 603998-49-8P  
603998-50-1P 603998-52-3P 603998-54-5P  
603998-74-9P 603998-75-0P 603998-76-1P  
603998-84-1P 603998-86-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of condensed heterocyclic compds. such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivs. as calcitonin agonists for drugs)

RN 603998-46-5 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[(2,3-dihydro-1H-

inden-1-yl)amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-48-7 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[2,3-dihydro-1H-inden-1-yl)amino]carbonyl]-2-furanyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 603998-49-8 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 603998-50-1 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-thiazolyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-52-3 CAPLUS

CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-oxazolyl]-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-54-5 CAPLUS

CN Benzamide, 4-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-3-[(trifluoroacetyl)amino]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-[(1R)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-74-9 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-2-(4-methylpentyl)-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-75-0 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(3,3,3-trifluoropropyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-76-1 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[(2,4-difluorophenyl)methyl]-4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-84-1 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-nitrophenyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 603998-86-3 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(phenylmethyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:33:00 ON 06 NOV 2006)

FILE 'REGISTRY' ENTERED AT 14:36:04 ON 06 NOV 2006

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 12 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:36:43 ON 06 NOV 2006

L4 2 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.14	179.13

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-1.50

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:38:00 ON 06 NOV 2006